title: Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
abstract: Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation. Here we describe the identification and development of specific, selective and orally active small-molecule inhibitors of PI3Kgamma (encoded by Pik3cg). We show that Pik3cg(-/-) mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kgamma as a therapeutic target. We also describe that oral treatment with a PI3Kgamma inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg(-/-) mice. Our results identify selective PI3Kgamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.
authors.affiliation: Serono Pharmaceutical Research Institute, Serono International S.A., 14, Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Camps
authors.forename: Thomas
authors.initials: T
authors.lastname: Rückle
authors.forename: Hong
authors.initials: H
authors.lastname: Ji
authors.forename: Vittoria
authors.initials: V
authors.lastname: Ardissone
authors.forename: Felix
authors.initials: F
authors.lastname: Rintelen
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Shaw
authors.forename: Chiara
authors.initials: C
authors.lastname: Ferrandi
authors.forename: Christian
authors.initials: C
authors.lastname: Chabert
authors.forename: Corine
authors.initials: C
authors.lastname: Gillieron
authors.forename: Bernard
authors.initials: B
authors.lastname: Françon
authors.forename: Thierry
authors.initials: T
authors.lastname: Martin
authors.forename: Denise
authors.initials: D
authors.lastname: Gretener
authors.forename: Dominique
authors.initials: D
authors.lastname: Perrin
authors.forename: Didier
authors.initials: D
authors.lastname: Leroy
authors.forename: Pierre-Alain
authors.initials: PA
authors.lastname: Vitte
authors.forename: Emilio
authors.initials: E
authors.lastname: Hirsch
authors.forename: Matthias P
authors.initials: MP
authors.lastname: Wymann
authors.forename: Rocco
authors.initials: R
authors.lastname: Cirillo
authors.forename: Matthias K
authors.initials: MK
authors.lastname: Schwarz
authors.forename: Christian
authors.initials: C
authors.lastname: Rommel
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000139:chemically induced / Q000188:drug therapy*; D001665:Binding Sites; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D004149:Dioxoles / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D007527:Isoenzymes; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D018345:Mice, Knockout; D008969:Molecular Sequence Data; D015394:Molecular Structure; D010538:Peritonitis / Q000139:chemically induced / Q000188:drug therapy; D019869:Phosphatidylinositol 3-Kinases / Q000737:chemistry; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011810:Quinoxalines / Q000737:chemistry / Q000627:therapeutic use*; D015398:Signal Transduction; D013329:Structure-Activity Relationship; D045162:Thiazolidinediones / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D004149:Dioxoles; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011810:Quinoxalines; D045162:Thiazolidinediones; C505145:5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione; C505144:5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione